Adamis Pharmaceuticals Corporation Stock News

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) with the stream of -1.83% also noticed, India Synthetic Biologics, Inc. (AMEX:SYN) encountered a rapid change of -4.77% in the last hour of Friday’s trading session. … The post Top-notch Stock: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Synthetic Biologics, Inc. (AMEX:SYN) appeared first on Stocks Equity .

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) with the stream of -4.76% also noticed, India BEST Inc. (NYSE:BEST) encountered a rapid change of -5.59% in the last hour of Monday’s trading session. Adamis … The post Stock Mover: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), BEST Inc. (NYSE:BEST) appeared first on Stocks Equity .

Adamis Pharmaceuticals (ADMP) chairman Richard C. Williams to retire effective April 15, 2022.“We admire Dick for his work ethic and wish him all the best in his retirement." said CEO…

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022.

Adamis Pharmaceuticals <> said the Data Safety Monitoring Board ((DSMB)) determined that its phase 2/3 trial of Tempol to treat COVID-19 can continue as no safety or clinical…

Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to conti

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COVID-19, an ad-hoc meeting of the Data Safety Monitoring Board (DSMB) was held to evaluate interim clinical and safety data for the trial. The DSMB is composed of subject matter experts and can unblind the data to determine the treatment effects of the subjects in the trial. Based on an analysis of the data, the DSMB determined that the study can continue, as there were no safety or clinical concerns identified. The data from the first 50 subjects will be reviewed again in March when the DSMB will examine additional clinical and safety data as part of the first planned interim analysis. "We are pleased with the progress of the trial, which has already exceeded the required number of subjects (124) for the second planned interim DSMB analysis," said Dr.

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2

Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease p

These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NEW YORK , Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTI, DIDI, HOOD, BITF, and ADMP. Full story available on Benzinga.com

These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (F